Abstract: The invention provides compounds of formula I: wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer and infections using compounds of formula I.

Abstract: The invention described herein is a method of identifying and changing amino acid residues that affect the stability of a protein and thereby to “adjust” the stability of a protein under particular conditions, e.g., to function at lower or higher temperatures. The residues modified in the method are chosen such that they are not in or interact with an active site or binding site of the protein, and therefore the mode of action or interaction of the protein on substrates remains unchanged. The method has wide applicability to any situation where a protein would be a better match to a pre-existing or new process if the functional optimum of the protein under particular conditions were different. Among others, the method is useful to produce proteins for bioremediation, food technology and enzymes for detergents.

Abstract: The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.

Abstract: Phthalocyanine compounds are disclosed having a structure according to formula I as shown below: ##STR1##

Abstract: A process for forming piezoelectric composites allows for novel composite designs, including composites with different polarizable material regions and composites with a gradient in volume fraction of polarizable material. Composites with fine-scale microstructures may be formed. The new forming method is an improvement to the traditional "dice and fill" technique currently being utilized to form piezoelectric composites.